NSTM (NovelStem International) Moat Score: 1/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NovelStem International Moat Score?

NovelStem International NSTM Moat Score is 1 as of Aug. 01, 2026. The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, NovelStem International ranks better than 65.42% on this metric.

NovelStem International has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

NovelStem International has No Moat: NovelStem International Corp lacks significant market share, intellectual property, and brand strength. The company operates in a highly competitive biotech industry with no discernible competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes NovelStem International might have No Moat - Very weak/transient advantages.

NovelStem International  (OTCPK:NSTM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

NovelStem International Moat Score Related Terms

NSTM vs NOTVQ, PRPH, IDTA: Moat Score Comparison

For the Diagnostics & Research subindustry, NovelStem International's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovelStem International Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Moat Score distribution charts can be found below:

* The bar in red indicates where NovelStem International's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
NovelStem International (NSTM) has a Moat Score of 1 as of Aug. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, NovelStem International ranks #74 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 34.6%.
Is NovelStem International's Moat Score too high?
NovelStem International's current Moat Score is 1. Based on the distribution chart, NovelStem International ranks #74 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does NovelStem International's Moat Score compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #74 out of 214 companies for Moat Score. This puts NovelStem International in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. NovelStem International's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current Moat Score of 1. The current Moat Score is 1. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For NovelStem International (NSTM), the current Moat Score is 1 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovelStem International Business Description

Address 7740 Cavern Lane, Suite 100, Parkland, FL, USA, 33067
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.